Trevi Therapeutics (TRVI) Short-term Investments (2022 - 2026)
Trevi Therapeutics' quarterly Short-term Investments came in at $152.4 million in Q1 2026, up 81.65% year-on-year from $83.9 million in Q1 2025, and down 10.02% quarter-over-quarter from $169.3 million in Q4 2025.
Trevi Therapeutics has reported Short-term Investments for 5 years, with the latest figure at $152.4 million in Q1 2026.
- For the quarter ending Q1 2026, Short-term Investments rose 81.65% year-over-year to $152.4 million; the trailing twelve-month figure through Mar 2026 stood at $152.4 million (up 81.65% YoY), and the FY2025 full-year result was $169.3 million, up 130.32% from the prior year.
- Short-term Investments for Q1 2026 stood at $152.4 million, down from $169.3 million in the prior quarter.
- The five-year high for Short-term Investments was $169.3 million in Q4 2025, with the low at $49.4 million in Q3 2024.
- Average Short-term Investments over 5 years is $86.4 million, with a median of $77.0 million recorded in 2023.
- Year-over-year, Short-term Investments sank 53.14% in 2023 and jumped 179.24% in 2025.
- Tracing TRVI's Short-term Investments over 5 years: stood at $107.9 million in 2022, then slumped by 53.14% to $50.6 million in 2023, then surged by 45.38% to $73.5 million in 2024, then jumped by 130.32% to $169.3 million in 2025, then decreased by 10.02% to $152.4 million in 2026.
- The last three Short-term Investments figures came in at $152.4 million (Q1 2026), $169.3 million (Q4 2025), and $138.1 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Trevi Therapeutics | 2.02 Bn | 1.85 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 152.37 Mn |
| Dec 31, 2025 | 169.35 Mn |
| Sep 30, 2025 | 138.06 Mn |
| Jun 30, 2025 | 86.83 Mn |
| Mar 31, 2025 | 83.88 Mn |
| Dec 31, 2024 | 73.53 Mn |
| Sep 30, 2024 | 49.44 Mn |
| Jun 30, 2024 | 56.53 Mn |
| Mar 31, 2024 | 59.01 Mn |
| Dec 31, 2023 | 50.57 Mn |
| Sep 30, 2023 | 62.90 Mn |
| Jun 30, 2023 | 80.40 Mn |
| Mar 31, 2023 | 99.61 Mn |
| Dec 31, 2022 | 107.92 Mn |
| Sep 30, 2022 | 59.03 Mn |
| Jun 30, 2022 | 53.16 Mn |